Hematopoietic stem cell transplantation in Switzerland: a comprehensive quality control report on centre effect

Passweg, J; Baldomero, H; Stern, M; Bargetzi, M; Ghielmini, M; Leibundgut, K; Duchosal, M; Hess, U; Seger, R; Buhrfeind, E; Schanz, U; Gratwohl, A (2010). Hematopoietic stem cell transplantation in Switzerland: a comprehensive quality control report on centre effect. Swiss medical weekly, 140(23-24), pp. 326-334. Muttenz: EMH Schweizerischer Ärzteverlag

Full text not available from this repository.

QUESTIONS UNDER STUDY / PRINCIPLES: Interest groups advocate centre-specific outcome data as a useful tool for patients in choosing a hospital for their treatment and for decision-making by politicians and the insurance industry. Haematopoietic stem cell transplantation (HSCT) requires significant infrastructure and represents a cost-intensive procedure. It therefore qualifies as a prime target for such a policy. METHODS: We made use of the comprehensive database of the Swiss Blood Stem Cells Transplant Group (SBST) to evaluate potential use of mortality rates. Nine institutions reported a total of 4717 HSCT - 1427 allogeneic (30.3%), 3290 autologous (69.7%) - in 3808 patients between the years 1997 and 2008. Data were analysed for survival- and transplantation-related mortality (TRM) at day 100 and at 5 years. RESULTS: The data showed marked and significant differences between centres in unadjusted analyses. These differences were absent or marginal when the results were adjusted for disease, year of transplant and the EBMT risk score (a score incorporating patient age, disease stage, time interval between diagnosis and transplantation, and, for allogeneic transplants, donor type and donor-recipient gender combination) in a multivariable analysis. CONCLUSIONS: These data indicate comparable quality among centres in Switzerland. They show that comparison of crude centre-specific outcome data without adjustment for the patient mix may be misleading. Mandatory data collection and systematic review of all cases within a comprehensive quality management system might, in contrast, serve as a model to ascertain the quality of other cost-intensive therapies in Switzerland.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine

UniBE Contributor:

Leibundgut, Kurt

ISSN:

1424-7860

Publisher:

EMH Schweizerischer Ärzteverlag

Language:

English

Submitter:

Anette van Dorland

Date Deposited:

04 Oct 2013 14:07

Last Modified:

05 Dec 2022 14:00

PubMed ID:

20349362

Web of Science ID:

000279763000001

URI:

https://boris.unibe.ch/id/eprint/172 (FactScience: 196604)

Actions (login required)

Edit item Edit item
Provide Feedback